Egaba 75 mg (Capsule)
Unit Price: ৳ 17.00 (3 x 10: ৳ 510.00)
Strip Price: ৳ 170.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Pregabalin |
| Company | Euro pharma ltd |
| Also available as |
Indications
- Neuropathic pain associated with diabetic peripheral neuropathy (DPN)
- Postherpetic neuralgia (PHN)
- Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older
- Fibromyalgia
- Neuropathic pain associated with spinal cord injury
Pharmacology
- Structural derivative of gamma-aminobutyric acid (GABA)
- Binds with high affinity to the alpha2-delta site
- Mechanism of action not fully elucidated
Dosage
- Maximum recommended dose of Pregabalin is 100 mg three times a day (300 mg/day)
- Dosing should begin at 50 mg three times a day (150 mg/day)
- Recommended dose of Pregabalin for postherpetic neuralgia is 75 to 150 mg two times a day or 50 to 100 mg three times a day (150 to 300 mg/day)
- Recommended dose of Pregabalin for fibromyalgia is 300 to 450 mg/day
Administration
- Route of administration is oral
- Can be taken with or without food
- Pregabalin CR tablet should be administered after an evening meal
Interaction
- Unlikely to be involved in significant pharmacokinetic drug interactions
- Not applicable for drug interaction with food and others
Contraindications
- Contraindicated in patients with known hypersensitivity to Pregabalin or any of its components
Side Effects
- Most common side effects in adults are dizziness, somnolence, dry mouth, edema, blurred vision, weight gain and thinking abnormal
- Most common side effects in pediatric patients for the treatment of partial onset seizures are increased weight and increased appetite
Pregnancy & Lactation
- No adequate and well-controlled studies with pregabalin in pregnant women
- Small amounts of pregabalin detected in the milk of lactating women
Precautions & Warnings
- Angioedema can occur and may be associated with life threatening respiratory compromise
- Increased risk of suicidal thoughts or behavior
- Respiratory depression may occur when used with concomitant CNS depressants
- May cause dizziness and somnolence
Use in Special Populations
- Safety and effectiveness in pediatric patients not established for certain conditions
Overdose Effects
- Signs and symptoms include reduced consciousness, depression/anxiety, confusional state, agitation, restlessness, seizures and heart block
- No specific antidote
Therapeutic Class
- Adjunct anti-epileptic drugs
- Primary anti-epileptic drugs
Storage Conditions
- Keep in a cool & dry place (below 30°C), protected from light & moisture
- Keep out of the reach of children
Chemical Structure
- Molecular Formula: C8H17NO2
- Chemical Structure: Image of chemical structure provided
Common Questions about Egaba 75 mg Capsule
- Information on the medication, usage, frequency, storage, and possible side effects
Dosage Conversion
- Table of Pregabalin tablet total daily dose and Pregabalin CR capsule dose
Maximum Dose
- Maximum recommended dose of Pregabalin CR capsule is 660 mg once daily
Pregnancy Risk
- Pregnant women should be advised of the potential risk to a fetus
Breastfeeding
- Not recommended during treatment with pregabalin
Discontinuation
- Egaba should be gradually tapered over a minimum of 1 week
Children & Adolescents
- Safety and effectiveness not established for specific age groups and conditions
Angioedema Warning
- Egaba should be discontinued immediately if angioedema occurs
Suicidal Thoughts Risk
- Increased risk of suicidal thoughts or behavior with Egaba
Respiratory Depression
- May occur with Egaba when used with concomitant CNS depressants
Dizziness and Somnolence
- May cause dizziness and somnolence, impairing the ability to drive or operate machinery
Peripheral Edema
- Egaba may cause peripheral edema
Medication Elimination
- Elimination of unabsorbed drug may be attempted by emesis or gastric lavage
Storage Instructions
- Instructions for the storage and disposal of Egaba 75 mg Capsule
Medication Use
- Egaba 75 mg Capsule should be taken as per the dose and duration prescribed by the doctor
Visual Changes
- Egaba 75 mg Capsule may cause blurring or loss of vision
Behavioral Changes
- Inform your doctor if you develop any unusual changes in mood or behavior, new or worsening depression, or suicidal thoughts or behavior
Rapid Discontinuation Warning
- Increased seizure frequency or other adverse reactions may occur if Egaba is rapidly discontinued
Postherpetic Neuralgia Dosing
- Detailed dosing information for postherpetic neuralgia
Fibromyalgia Dosing
- Detailed dosing information for fibromyalgia
Spinal Cord Injury Dosing
- Detailed dosing information for neuropathic pain associated with spinal cord injury
Thiazolidinedione Interaction
- Caution should be exercised when coadministering Egaba and thiazolidinedione antidiabetic agents
Adjunctive Therapy Age Restriction
- Safety and effectiveness in pediatric patients below the age of 1 month not established
Pediatric Tablet Effectiveness
- The safety and effectiveness of Egaba extended-release tablet in pediatric patients not established
Overdose Treatment
- General supportive care of the patient is indicated including monitoring of vital signs and observation of the clinical status of the patient